Evaluation of SSTR2 Expression in SI-NETs and Relation to Overall Survival after PRRT

• Published in: Cancers Vol. 13; no. 9; p. 2035
• Main Authors: Elf, Anna-Karin, Johanson, Viktor, Marin, Ida, Bergström, Anders, Nilsson, Ola, Svensson, Johanna, Wängberg, Bo, Bernhardt, Peter, Elias, Erik
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 23.04.2021; MDPI
• Subjects: Cancer and Oncology; Cancer och onkologi; Cloning; Hypotheses; Intestine; Lymph nodes; Metastases; Metastasis; Neuroendocrine tumors; Overall survival; Patients; Peptide receptor radionuclide therapy (PRRT); Radiation therapy; Small intestinal neuroendocrine tumor (SI-NET); Somatostatin; Somatostatin receptor expression; Somatostatin receptors; Statistical analysis; Survival; Survival analysis; Synaptophysin; Tumors; Denmark; Glostrup Denmark; overall survival; somatostatin receptor expression; peptide receptor radionuclide therapy (PRRT); small intestinal neuroendocrine tumor (SI-NET)
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13092035

(1) Purpose: Small intestinal neuroendocrine tumors (SI-NETs) often present with distant metastases at diagnosis. Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues is a systemic treatment that increases overall survival (OS) in SI-NET patients with stage IV disease. However, the treatment response after PRRT, which targets somatostatin receptor 2 (SSTR2), is variable and predictive factors have not been established. This exploratory study aims to evaluate if SSTR2 expression in SI-NETs could be used to predict OS after PRRT treatment. (2) Methods: Using a previously constructed Tissue Micro Array (TMA) we identified tissue samples from 42 patients that had received PRRT treatment during 2006-2017 at Sahlgrenska University hospital. Immunohistochemical expression of SSTR2, Ki-67 and neuroendocrine markers synaptophysin and Chromogranin A (CgA) were assessed. A retrospective estimation of Lu-DOTATATE uptake in 33 patients was performed. Data regarding OS and non-surgical treatment after PRRT were collected. Another subgroup of 34 patients with paired samples from 3 tumor sites (primary tumor, lymph node and liver metastases) was identified in the TMA. The SSTR2 expression was assessed in corresponding tissue samples ( = 102). (3) Results: The patients were grouped into Low SSTR2 or High SSTR2 groups based upon on levels of SSTR2 expression. There was no significant difference in Lu-DOTATATE uptake between the groups. The patients in the Low SSTR2 group had significantly longer OS after PRRT than the patients in the High SSTR2 group ( = 0.049). PRRT treated patients with low SSTR2 expression received less additional treatment compared with patients with high SSTR2 expression. SSTR2 expression did not vary between tumor sites but correlated within patients. (4) Conclusion: The results from the present study suggest that retrospective evaluation of SSTR2 expression in resected tumors cannot be used to predict OS after PRRT.